LaBrosse Nicole
- SEC CIK
- 0001910662
No open-market purchases or sales filed in the past year.
Current role at each company
- HALO Halozyme Therapeutics, Inc.SVP, CHIEF FINANCIAL OFFICERas of Feb 24, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists LaBrosse Nicole as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2025 (view filing) | Sep 22 | 1 day | LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER | SSale | −2.23K | $77.95 | −$173.6K | −9.2%22.1K after | 2 lots10b5-1 |
| Sep 11, 2025 (view filing) | Sep 10 | 1 day | LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER | SSale | −20.0K | $75.71 | −$1.51M | −45.1%24.3K after | 2 lots10b5-1 |
| Jul 23, 2024 (view filing) | Jul 22 | 1 day | LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER | SSale | −5.00K | $53.93 | −$269.6K | −24.4%15.5K after | 2 lots10b5-1 |
| Jun 28, 2024 (view filing) | Jun 26-28 | 2 days | LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER | SSale | −30.0K | $51.93 | −$1.56M | −66.0%15.5K after | 3 lots10b5-1 |
| Feb 21, 2023 (view filing) | Feb 16 | 5 days | LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER | SSale | −2.52K | $49.26 | −$124.4K | −21.8%9.07K after | |
| Nov 16, 2022 (view filing) | Nov 15 | 1 day | LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER | SSale | −5.00K | $53.81 | −$269.1K | −55.3%4.04K after | 2 lots |